Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Our ViewPlate microplates are engineered for bottom reading systems. This high quality microplate can be utilized in your cell based assay for superior results.
Leveraging years of assay and instrument experience in plate detection, PerkinElmer designs better microplates for better performance that guarantees better results for all PerkinElmer applications.
Well format: 96-well
|Number of Rows||8|
|Number of Columns||12|
|Well volume||360 µL|
|Recommended working volume||80 µL- 350 µL|
|Well diameter (mm)||6.1|
|Well depth (mm)||11.4|
|A1 to top offset (mm)||11.3|
|A1 to side offset (mm)||14.3|
|Well-to-well spacing (mm)||9|
|Coating Treatment||TC-treated, Sterile|
|Detection Method||Confocal Imaging, Luminescence, High Content Imaging, Time-Resolved Fluorescence (TRF & TR-FRET), Radiometric|
|Product Brand Name||ViewPlate|
|Unit Size||Case of 50|
|Wells Number||96 well plate|
A variety of chemotherapeutic drugs with different modes of action have been developed and tested as potential therapies for colorectal cancer. Characterizing the effects of potential drugs with different modes of action is a key part of the process.
In this application note you will learn:
Find out about our range of integrated solutions for drug discovery screening in this e-brochure.
Our screening solutions for high-throughput screening, phenotypic screening and data analysis help to streamline drug discovery workflows in labs across the globe. Our portfolio includes automated liquid handling, assays and reagents, imaging and detection systems, and informatics.
Working independently or together, with our solutions you can achieve consistent and accurate results. By accelerating the identification and characterization of effective and safe drug candidates, the PerkinElmer portfolio enables you to optimize efficiency in your lab and deliver more actionable, real-world results.
Download the brochure to learn more about how we can partner with you so that you can discover smarter, more effective, data-driven breakthroughs in the critical screening stages of drug discovery and development.